Human iPSC-Derived 3D Hepatic Organoids in a Miniaturized Dynamic Culture System

Area of Science:

• Biotechnology
• Stem Cell Research
• Drug Development

Background:

• Drug development is costly and time-consuming, with hepatotoxicity being a major cause of market withdrawal.
• Animal models for preclinical drug testing have limitations due to interspecies metabolic differences.
• Human induced pluripotent stem cells (hiPSCs) provide a promising alternative for in vitro drug testing.

Purpose of the Study:

• To develop a miniaturized hepatic organoid model using hiPSC-derived cells for drug testing.
• To evaluate the efficacy of static and dynamic culture methods for hepatic organoids.
• To assess the potential of hiPSC-derived liver organoids as a replacement for animal models in toxicology.

Main Methods:

• Generation of hepatic organoids from hiPSC-derived mesenchymal stem cells, hepatocytes, and endothelial cells.
• Cultivation of organoids using static and dynamic in vitro culture systems.
• Comparison of hiPSC-derived hepatic organoids with induced hepatocyte spheroids for culture stability.

Main Results:

• Miniaturized hepatic organoids derived from hiPSCs could be maintained in culture for up to one week.
• Induced hepatocyte spheroids could not be maintained for the same duration.
• The established culture timeframe is potentially sufficient for pharmacological and toxicological screening.

Conclusions:

• hiPSC-derived liver organoids offer a viable in vitro model for drug testing.
• This model shows potential to complement or replace traditional animal testing in preclinical toxicology.
• Further development could enhance the utility of hiPSC-based liver models for drug safety assessment.